• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

FDA approves STAAR Surgical’s EVO Visian ICL for myopia


US commercialization of EVO will begin immediately in select cities across the country.

FDA approves STAAR Surgical’s EVO Visian ICL for myopia

Image courtesy of STAAR Surgical.

STAAR Surgical announced Monday that the FDA has approved its EVO/EVO+ Visian Implantable Collamer Lens (ICL) for the correction of myopia and myopia with astigmatism.

According to the company, EVO—a biocompatible implantable lens— is designed to be used in phakic eye treatment for patients ages 21 to 45 for the following:

  • correction/reduction of myopia in patients with spherical equivalent ranging from -3.0 D to -20.0 D at the spectacle plane;
  • correction/reduction of myopic astigmatism in patients with spherical equivalent ranging from -3.0 D to -20.0 D with cylinder of 1.0 D to 4.0 D at the spectacle plane;
  • with an anterior chamber depth (ACD) of 3.00 mm or greater, when measured from the corneal endothelium to the anterior surface of the crystalline lens;
  • a stable refractive history (within 0.5 D for 1 year prior to implantation)

EVOs are implanted within the posterior chamber of the eye, directly behind the iris and in front of the natural crystalline lens, according to the news release.

EVO works as a lens-based alternative for the correction and reduction of refractive error in glasses and/or contact lens wearers for distance vision correction.

Over 1 million EVO lenses have been implanted by doctors outside of the US, and a survey found that 99.4% of EVO patients stated they would undergo the procedure again, according to STAAR Surgical President/CEO Caren Mason.

“Sales of EVO lenses outside of the US increased 51% in 2021 and have more than doubled since 2018, which speaks to the increasing choice by patients and our surgeon partners for EVO as a premium an primary solution for vision correction,” Mason said in a release.

Mason further stated that surgeons will be trained and certified for EVO, and begin implanting the lenses in the near future in select cities across the country.

“Commercialization of EVO will begin immediately and be supported by a nationwide advertising, marketing, and public relations campaign,” he added.

Scott D. Barnes, MD, chief medical officer at STAAR Surgical, stated in a release that, unlike LASIK, the EVO lens can be added to a patient’s eye through a fairly quick surgical procedure involving no removal of corneal tissue. Additionally, the lens can be removed by a physician, if desired.

“Results from our recent U.S. clinical trial are consistent with the more than one million EVO lenses that have already been implanted around the world,” he stated.

Read more myopia content

Related Videos
William Reindel, OD
David A. Berntsen, OD, PhD, FAAO, outlines his presentation on the BLINK 2 study presented at the 2024 ARVO meeting
Neda Shamie, MD, details the upcoming CIME 2024 meeting
Charles Leclercq, CEO of ARxVision, details the new ARx AI headset and its uses
Dr Brianna Rhue, OD, FAAO, FSLS chat about her upcoming presentation at Vision Expo East 2024
The Vision Council CEO Ashley Mills gives a preview of the 2024 Vision Expo East event
© 2024 MJH Life Sciences

All rights reserved.